Esperion Therapeutics

From Wikipedia, the free encyclopedia
Esperion Therapeutics, Inc.
Traded as NASDAQ: ESPR
Industry Pharmaceutical
Founded 1998 (1998)
Headquarters Plymouth, Michigan, U.S.
Key people Roger S. Newton (President & CEO)
Website Esperion.com

Esperion Therapeutics, Inc. is a venture-capital funded company, sponsored by TL Ventures, Asset Management Ventures, Oak Investment Partners and HealthCap, created to discover and develop therapies to prevent, treat, and reverse cardiovascular and metabolic diseases. Esperion is located in Plymouth, Michigan. Esperion is best known for initial development of ApoA-1 Milano protein as an atherosclerosis therapy.

History

Esperion was founded in 1998. In year 2000, the company had been listed on NASDAQ (Ticker symbol: ESPR). The company was acquired by Pfizer for $1.3 billion in 2004. Pfizer divested it as an independent company in 2008.[1][2] As part of the repurchase agreement, Pfizer continues to hold an undisclosed share of Esperion's net worth.

Product Candidates

Esperion publicly state they have agent ETC-1002[3] in development work. Roger S. Newton, PhD, FAHA,[4] who many credit with the eventual developmental success of Lipitor within Pfizer, and who abandoned Pfizer, risking his net worth to found Esperion Therapeutics and devote his research skills to developing ApoA-1 Milano, managed to buy back Esperion and patent rights to much of his work. He continues to work on developing small-molecule HDL function enhancing agents.

References

  1. ↑ "History". 
  2. ↑ Catherine Shaffer (2008). "Pfizer jettisons Esperion". Nature Biotechnology 26: 724–725. doi:10.1038/nbt0708-724. 
  3. ↑ http://www.esperion.com/products-research/product-candidates.php
  4. ↑ http://www.esperion.com/about-us/management.php


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.